Urticaria

This phase 2 trial tested KVD824, an oral pill, to prevent swelling attacks in people with hereditary angioedema types I and II. The study planned to compare three doses against a placebo over several months. However, the trial was terminated early with only 33 participants, so t…

This study tested an oral drug called INF904 in people with moderate to severe chronic spontaneous urticaria (long-term hives) or hidradenitis suppurativa (a painful skin condition). The trial was open-label and lasted 28 days of treatment plus follow-up. It aimed to check safety…

This Phase 2 trial tested an experimental drug called EP262 in 113 people with chronic spontaneous urticaria (long-lasting hives with no clear cause). Participants took either EP262 or a placebo daily for 6 weeks, while continuing their usual antihistamines. The study aimed to se…

This early-stage trial tested a single dose of a drug called briquilimab in 27 adults with chronic hives caused by cold or friction that did not improve with standard allergy pills. The main goal was to check safety and see if the drug could reduce symptoms. However, the trial wa…

This study aimed to find biomarkers (measurable substances in the blood) that could help doctors diagnose bradykinin angioedema and predict how severe attacks might be. The condition causes sudden, unpredictable swelling, and current tests don't work well for all types. Researche…